Major insurers offer $55 million to lower generic drug costs

Major insurers offer $55 million to lower generic drug costs

A nonprofit that develops and sells cheaper drugs will receive a $55 million investment from the Blue Cross Blue Shield Association and associated organizations to create cheaper versions of expensive generic drugs.

The nonprofit Civica Rx, which already sells drugs to across the United States, reached the deal with the Blue Cross Blue Shield Association and 18 of its member organizations, which insure about 40 million people, The New York Times reported.

The insurers and Civica did not name specific drugs that would be targeted because they did not want to provide that information to potential business rivals. They said they would begin with seven to 10 drugs that have little competition and that some of the first medications could become available by early 2022, The Times reported.

The effort could eventually target insulin, according to Maureen Sullivan, the chief strategy and innovation officer at the Blue Cross Blue Shield Association. Insulin has been on the for decades, but recent spikes in its price have made it difficult for many patients to afford, The Times reported.

This "will not solve all the problems of the world, but we do know that 90 percent of prescriptions are generic, and there are certain parts of the generic markets that are not functioning like competitive markets should," Dan Liljenquist, chair of Civica's board, told The Times. "And we intend to compete in those markets."

More information: The New York Times Article

Copyright © 2020 HealthDay. All rights reserved.

Citation: Major insurers offer $55 million to lower generic drug costs (2020, January 24) retrieved 3 February 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Name-brand medications driving spike in U.S. drug spending


Feedback to editors